22nd Century Group, Inc. (NASDAQ:XXII) Short Interest Update

22nd Century Group, Inc. (NASDAQ:XXII) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totalling 307,300 shares, a growth of 40.8% from the May 31st total of 218,300 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average trading volume of 1,660,000 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded 22nd Century Group to a “sell” rating in a research note on Thursday, May 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, 22nd Century Group has an average rating of “Hold” and an average target price of $100.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in 22nd Century Group stock. Anson Funds Management LP increased its stake in shares of 22nd Century Group, Inc. (NASDAQ:XXII) by 106.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 6,577,814 shares of the biotechnology company’s stock after purchasing an additional 3,399,323 shares during the quarter. Anson Funds Management LP owned 83.28% of 22nd Century Group worth $789,000 at the end of the most recent quarter. 18.06% of the stock is currently owned by institutional investors and hedge funds.

22nd Century Group Price Performance

Shares of 22nd Century Group stock opened at $0.75 on Monday. The firm has a market cap of $6.18 million, a PE ratio of -0.01 and a beta of 1.42. 22nd Century Group has a 12 month low of $0.58 and a 12 month high of $110.24. The stock has a 50 day moving average of $1.19 and a 200 day moving average of $23.45. The company has a current ratio of 0.54, a quick ratio of 0.43 and a debt-to-equity ratio of 0.01.

22nd Century Group (NASDAQ:XXII) last announced its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($10.56) earnings per share for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 233.06%. The business had revenue of $7.36 million during the quarter.

About 22nd Century Group

22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.